Trials / Completed
CompletedNCT03926013
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects With Advanced Stage Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-63898081 | JNJ-63898081 will be administered. |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2021-08-23
- Completion
- 2021-09-02
- First posted
- 2019-04-24
- Last updated
- 2022-11-07
Locations
7 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03926013. Inclusion in this directory is not an endorsement.